Get access to our best features
Get Started
Subscribe
Israeli-Palestinian Conflict
2024 US Election
US Politics
Donald Trump
Joe Biden
Earth Day
Baseball
NBA
Senate
Education
US Social Issues
US Crime
US Economy
Get access to our best features
Get Started
Published 1 year ago

Israeli co Nectin Therapeutics raises $25m

Summary by Ground News
Jerusalem-based Nectin is developing novel targeted immunotherapies to address resistance to approved immuno-oncology treatments. The company also announced today dosing of the first patient in its Phase I clinical trial of NTX1088, the company's first-in-class PVR (CD155) blocker.

0 Articles

All
Left
Center
Right
GlobesGlobes

Israeli co Nectin Therapeutics raises $25m

Jerusalem-based Nectin is developing novel targeted immunotherapies to address resistance to approved immuno-oncology treatments.

1 year ago
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Trending Topics
Ground News logo
US
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble Newsletter
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc.
News
For You
Search
BlindspotLocal